|
G |
Acmsd |
aminocarboxymuconate semialdehyde decarboxylase |
increases abundance |
EXP |
ACMSD protein results in increased abundance of NAD |
CTD |
PMID:17896587 |
|
NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
multiple interactions |
ISO |
NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] |
CTD |
PMID:15720144 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
multiple interactions |
ISO |
[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] |
CTD |
PMID:25446855 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
multiple interactions |
ISO |
[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] |
CTD |
PMID:25446855 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] |
CTD |
PMID:25446855 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:25536389 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions increases activity |
ISO |
[ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein] NAD results in increased activity of ALDH1A1 protein |
CTD |
PMID:10559215 PMID:10856427 PMID:21256123 PMID:22339434 PMID:25450233 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
multiple interactions |
ISO |
[ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde |
CTD |
PMID:7779080 |
|
NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions affects abundance affects binding |
ISO EXP |
[ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [[Ethanol co-treated with Lead] results in decreased expression of and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of ALDH2 protein] ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD ALDH2 protein binds to NAD Magnesium affects the reaction [NAD binds to ALDH2 protein] |
CTD |
PMID:10559215 PMID:15629893 PMID:15900217 PMID:21276780 PMID:22339434 PMID:23295226 PMID:37142061 More...
|
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
multiple interactions increases activity |
ISO |
[ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde NAD results in increased activity of ALDH3A1 protein |
CTD |
PMID:10856427 PMID:21256123 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
multiple interactions |
EXP |
NAD binds to and affects the activity of ALDH5A1 protein |
CTD |
PMID:18926807 |
|
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
ISO |
NAD results in decreased expression of BAX protein |
CTD |
PMID:12390773 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
NAD results in increased expression of BCL2 protein |
CTD |
PMID:12390773 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] |
CTD |
PMID:11461765 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase 1 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of BDH1 protein |
CTD |
PMID:25526675 |
|
NCBI chr11:69,302,534...69,343,173
Ensembl chr11:69,302,534...69,337,671
|
|
G |
Bdh2 |
3-hydroxybutyrate dehydrogenase 2 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of BDH2 protein |
CTD |
PMID:25526675 |
|
NCBI chr 2:223,702,410...223,723,076
Ensembl chr 2:223,702,412...223,723,072
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases oxidation |
ISO |
BMAL1 gene mutant form results in decreased oxidation of NAD |
CTD |
PMID:27056296 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] |
CTD |
PMID:24040102 PMID:24491677 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] |
CTD |
PMID:10334203 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr4 |
carbonyl reductase 4 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of CBR4 protein |
CTD |
PMID:25526675 |
|
NCBI chr16:28,629,928...28,684,230
Ensembl chr16:28,617,224...28,645,712
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
EXP |
NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] |
CTD |
PMID:22561310 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP |
NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] |
CTD |
PMID:22561310 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Chrna9 |
cholinergic receptor nicotinic alpha 9 subunit |
multiple interactions |
ISO |
CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr14:42,235,218...42,241,939
Ensembl chr14:42,235,226...42,242,192
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[NAD results in increased abundance of Reactive Oxygen Species] which results in increased expression of CSF2 protein |
CTD |
PMID:11752025 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cyb5b |
cytochrome b5 type B |
multiple interactions |
ISO |
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine |
CTD |
PMID:25170804 |
|
NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
affects binding multiple interactions |
ISO |
CYB5R3 protein binds to NAD [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine |
CTD |
PMID:16469290 PMID:25170804 |
|
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
multiple interactions |
ISO |
1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin] |
CTD |
PMID:28595002 |
|
NCBI chr10:106,006,404...106,008,293
|
|
G |
Dek |
DEK proto-oncogene |
increases oxidation |
ISO |
DEK protein results in increased oxidation of NAD |
CTD |
PMID:28558019 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Dhrs9 |
dehydrogenase/reductase 9 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of DHRS9 protein |
CTD |
PMID:25526675 |
|
NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
|
|
G |
Enox2 |
ecto-NOX disulfide-thiol exchanger 2 |
multiple interactions |
ISO |
[epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD |
CTD |
PMID:20518072 |
|
NCBI chr X:128,270,941...128,593,074
Ensembl chr X:128,271,074...128,593,039
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
multiple interactions increases metabolic processing increases ADP-ribosylation decreases abundance |
ISO |
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein] ERCC6 gene mutant form results in increased metabolism of NAD NAD results in increased ADP-ribosylation of ERCC6 protein ERCC6 gene mutant form results in decreased abundance of NAD nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Gale |
UDP-galactose-4-epimerase |
multiple interactions |
ISO |
NAD binds to and results in increased activity of GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Galnt1 |
polypeptide N-acetylgalactosaminyltransferase 1 |
increases expression |
ISO |
NAD results in increased expression of GALNT1 mRNA |
CTD |
PMID:29935245 |
|
NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO EXP |
[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
EXP |
NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] |
CTD |
PMID:22561310 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases abundance multiple interactions |
ISO |
GSK3B protein mutant form results in increased abundance of NAD metabolite 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:25246272 PMID:25536389 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
NAD inhibits the reaction [Doxorubicin results in decreased activity of GSR protein] |
CTD |
PMID:24491677 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
increases metabolic processing |
ISO |
HADH protein results in increased metabolism of NAD |
CTD |
PMID:10600649 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
multiple interactions |
ISO |
[Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein |
CTD |
PMID:25526675 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hpse |
heparanase |
increases expression |
EXP |
NAD results in increased expression of HPSE mRNA; NAD results in increased expression of HPSE protein |
CTD |
PMID:19429930 |
|
NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene] |
CTD |
PMID:10334203 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
multiple interactions |
ISO |
[Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein |
CTD |
PMID:25526675 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
increases reduction multiple interactions |
EXP ISO |
HSD11B2 protein results in increased reduction of NAD Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD] |
CTD |
PMID:26859423 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsd17b10 |
hydroxysteroid (17-beta) dehydrogenase 10 |
multiple interactions |
ISO |
[20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein |
CTD |
PMID:25526675 |
|
NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488
|
|
G |
Hsd17b11 |
hydroxysteroid (17-beta) dehydrogenase 11 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B11 protein |
CTD |
PMID:25526675 |
|
NCBI chr14:5,693,304...5,743,157
Ensembl chr14:5,711,964...5,743,161
|
|
G |
Hsd17b13 |
hydroxysteroid (17-beta) dehydrogenase 13 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B13 protein |
CTD |
PMID:25526675 |
|
NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166
|
|
G |
Hsd17b14 |
hydroxysteroid (17-beta) dehydrogenase 14 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B14 protein |
CTD |
PMID:25526675 |
|
NCBI chr 1:96,029,224...96,039,577
Ensembl chr 1:96,029,284...96,039,883
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B2 protein |
CTD |
PMID:25526675 |
|
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B4 protein |
CTD |
PMID:25526675 |
|
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Hsd17b6 |
hydroxysteroid (17-beta) dehydrogenase 6 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B6 protein |
CTD |
PMID:25526675 |
|
NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425
|
|
G |
Hsd17b8 |
hydroxysteroid (17-beta) dehydrogenase 8 |
multiple interactions |
ISO |
[Gossypol co-treated with NAD] binds to HSD17B8 protein |
CTD |
PMID:25526675 |
|
NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD3B1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD3B2 protein |
CTD |
PMID:25526675 |
|
NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hsd3b7 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD3B7 protein |
CTD |
PMID:25526675 |
|
NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression multiple interactions |
ISO |
NAD results in increased expression of IGFBP1 mRNA NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] |
CTD |
PMID:32781018 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein] |
CTD |
PMID:25536389 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Ldha |
lactate dehydrogenase A |
increases oxidation |
EXP |
LDHA protein results in increased oxidation of NAD |
CTD |
PMID:8632003 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Mir34a |
microRNA 34a |
decreases abundance multiple interactions |
ISO |
MIR34A mRNA results in decreased abundance of NAD [[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD] |
CTD |
PMID:23834033 |
|
NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Mtarc1 |
mitochondrial amidoxime reducing component 1 |
multiple interactions |
ISO |
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] |
CTD |
PMID:25170804 PMID:29856598 |
|
NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796
|
|
G |
Mtarc2 |
mitochondrial amidoxime reducing component 2 |
multiple interactions |
ISO |
[MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine |
CTD |
PMID:25170804 |
|
NCBI chr13:96,362,810...96,397,284
|
|
G |
Muc2 |
mucin 2, oligomeric mucus/gel-forming |
increases expression |
ISO |
NAD results in increased expression of MUC2 mRNA |
CTD |
PMID:29935245 |
|
NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756
|
|
G |
Nadk |
NAD kinase |
increases phosphorylation |
ISO |
NADK protein results in increased phosphorylation of NAD |
CTD |
PMID:22954684 |
|
NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322
|
|
G |
Nadsyn1 |
NAD synthetase 1 |
multiple interactions |
ISO |
[NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD |
CTD |
PMID:12547821 |
|
NCBI chr 1:198,981,559...199,009,853
Ensembl chr 1:198,981,604...199,009,869
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
increases chemical synthesis multiple interactions |
ISO |
NAMPT protein results in increased chemical synthesis of NAD [[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]] |
CTD |
PMID:23834033 PMID:25505128 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Ndufs4 |
NADH:ubiquinone oxidoreductase subunit S4 |
affects abundance |
ISO |
NDUFS4 protein affects the abundance of NAD |
CTD |
PMID:21383081 |
|
NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases oxidation multiple interactions |
EXP |
NQO1 protein results in increased oxidation of NAD NAD promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3] |
CTD |
PMID:27558805 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein |
CTD |
PMID:27026705 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
P2ry1 |
purinergic receptor P2Y1 |
multiple interactions |
ISO |
P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 2:145,241,975...145,248,186
Ensembl chr 2:145,241,849...145,248,457
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions affects abundance decreases abundance |
ISO EXP |
[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD] PARP1 protein affects the abundance of NAD [2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]] PARP1 protein results in decreased abundance of NAD 5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD] |
CTD |
PMID:11593040 PMID:15075382 PMID:15147502 PMID:17669606 PMID:19433264 PMID:25440059 PMID:25536389 PMID:27026705 PMID:27694308 PMID:35778544 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp10 |
poly (ADP-ribose) polymerase family, member 10 |
decreases abundance |
ISO |
PARP10 protein results in decreased abundance of NAD |
CTD |
PMID:33051211 |
|
NCBI chr 7:107,949,031...107,958,377
Ensembl chr 7:107,949,043...107,958,304
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
multiple interactions |
ISO |
PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions decreases activity |
EXP |
3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein] |
CTD |
PMID:18815186 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppt1 |
palmitoyl-protein thioesterase 1 |
affects abundance |
ISO |
PPT1 gene mutant form affects the abundance of NAD |
CTD |
PMID:21224254 |
|
NCBI chr 5:135,121,164...135,142,048
Ensembl chr 5:135,121,163...135,142,048
|
|
G |
Rdh10 |
retinol dehydrogenase 10 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of RDH10 protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:3,186,671...3,215,572
Ensembl chr 5:3,188,445...3,215,572
|
|
G |
Rdh16 |
retinol dehydrogenase 16 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of RDH16 protein |
CTD |
PMID:25526675 |
|
NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124
|
|
G |
Rdh5 |
retinol dehydrogenase 5 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of RDH5 protein |
CTD |
PMID:25526675 |
|
NCBI chr 7:1,341,172...1,346,863
Ensembl chr 7:1,340,934...1,351,558
|
|
G |
Sdr16c5 |
short chain dehydrogenase/reductase family 16C, member 5 |
affects activity multiple interactions |
ISO |
NAD affects the activity of SDR16C5 protein NAD binds to and results in increased activity of SDR16C5 protein |
CTD |
PMID:18926804 PMID:25526675 |
|
NCBI chr 5:17,018,813...17,043,974
Ensembl chr 5:17,018,813...17,040,970
|
|
G |
Sdr9c7 |
short chain dehydrogenase/reductase family 9C, member 7 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of SDR9C7 protein |
CTD |
PMID:25526675 |
|
NCBI chr 7:63,703,788...63,720,325
Ensembl chr 7:63,707,071...63,721,480
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases abundance increases activity increases response to substance |
ISO EXP |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein] SIRT1 protein results in decreased abundance of NAD NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein NAD results in increased activity of SIRT1 protein SIRT1 protein results in increased susceptibility to NAD |
CTD |
PMID:19288225 PMID:19928762 PMID:22561310 PMID:23834033 PMID:25536389 PMID:34216621 More...
|
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Smpd2 |
sphingomyelin phosphodiesterase 2 |
affects activity |
ISO |
NAD affects the activity of SMPD2 protein |
CTD |
PMID:20518072 |
|
NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441
|
|
G |
Sphk1 |
sphingosine kinase 1 |
decreases activity |
ISO |
NAD results in decreased activity of SPHK1 protein |
CTD |
PMID:20518072 |
|
NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240
|
|
G |
Taldo1 |
transaldolase 1 |
decreases abundance |
ISO |
TALDO1 gene mutant form results in decreased abundance of NAD |
CTD |
PMID:19436114 |
|
NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974
|
|
G |
Tgds |
TDP-glucose 4,6-dehydratase |
multiple interactions |
ISO |
NAD binds to and results in increased activity of TGDS protein |
CTD |
PMID:25526675 |
|
NCBI chr15:95,175,064...95,195,555
Ensembl chr15:95,174,608...95,195,554
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions decreases expression |
ISO |
[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] NAD results in decreased expression of TP53 protein NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein] |
CTD |
PMID:10334203 PMID:11461765 PMID:12390773 PMID:34216621 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tyr |
tyrosinase |
multiple interactions increases oxidation |
ISO |
ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD] |
CTD |
PMID:20685355 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:653,740...731,121
Ensembl chr 9:653,659...756,334
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
decreases reduction multiple interactions |
ISO |
XRCC1 gene mutant form results in decreased reduction of NAD [XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]] |
CTD |
PMID:30998386 PMID:35778544 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
|
G |
Acmsd |
aminocarboxymuconate semialdehyde decarboxylase |
increases abundance |
EXP |
ACMSD protein results in increased abundance of NAD |
CTD |
PMID:17896587 |
|
NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
multiple interactions |
ISO |
NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol] |
CTD |
PMID:15720144 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
multiple interactions |
ISO |
[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] |
CTD |
PMID:25446855 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
multiple interactions |
ISO |
[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] |
CTD |
PMID:25446855 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol] |
CTD |
PMID:25446855 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:25536389 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions increases activity |
ISO |
[ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein] NAD results in increased activity of ALDH1A1 protein |
CTD |
PMID:10559215 PMID:10856427 PMID:21256123 PMID:22339434 PMID:25450233 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
multiple interactions |
ISO |
[ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde |
CTD |
PMID:7779080 |
|
NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions affects binding affects abundance |
ISO EXP |
[ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [[Ethanol co-treated with Lead] results in decreased expression of and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of ALDH2 protein] ALDH2 protein binds to NAD NAD binds to ALDH2 protein Magnesium affects the reaction [NAD binds to ALDH2 protein] ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD |
CTD |
PMID:10559215 PMID:15629893 PMID:15900217 PMID:21276780 PMID:22339434 PMID:23295226 PMID:37142061 More...
|
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
multiple interactions increases activity |
ISO |
[ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde NAD results in increased activity of ALDH3A1 protein |
CTD |
PMID:10856427 PMID:21256123 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
multiple interactions |
EXP |
NAD binds to and affects the activity of ALDH5A1 protein |
CTD |
PMID:18926807 |
|
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
ISO |
NAD results in decreased expression of BAX protein |
CTD |
PMID:12390773 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
NAD results in increased expression of BCL2 protein |
CTD |
PMID:12390773 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
NAD inhibits the reaction [Acetaminophen results in decreased expression of BCL2L1 protein] |
CTD |
PMID:11461765 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdh1 |
3-hydroxybutyrate dehydrogenase 1 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of BDH1 protein |
CTD |
PMID:25526675 |
|
NCBI chr11:69,302,534...69,343,173
Ensembl chr11:69,302,534...69,337,671
|
|
G |
Bdh2 |
3-hydroxybutyrate dehydrogenase 2 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of BDH2 protein |
CTD |
PMID:25526675 |
|
NCBI chr 2:223,702,410...223,723,076
Ensembl chr 2:223,702,412...223,723,072
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases oxidation |
ISO |
BMAL1 gene mutant form results in decreased oxidation of NAD |
CTD |
PMID:27056296 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] |
CTD |
PMID:24040102 PMID:24491677 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] |
CTD |
PMID:10334203 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr4 |
carbonyl reductase 4 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of CBR4 protein |
CTD |
PMID:25526675 |
|
NCBI chr16:28,629,928...28,684,230
Ensembl chr16:28,617,224...28,645,712
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
EXP |
NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] |
CTD |
PMID:22561310 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP |
NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]] |
CTD |
PMID:22561310 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Chrna9 |
cholinergic receptor nicotinic alpha 9 subunit |
multiple interactions |
ISO |
CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr14:42,235,218...42,241,939
Ensembl chr14:42,235,226...42,242,192
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[NAD results in increased abundance of Reactive Oxygen Species] which results in increased expression of CSF2 protein |
CTD |
PMID:11752025 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cyb5b |
cytochrome b5 type B |
multiple interactions |
ISO |
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine |
CTD |
PMID:25170804 |
|
NCBI chr19:35,062,871...35,096,741
Ensembl chr19:35,062,813...35,098,249
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
affects binding multiple interactions |
ISO |
CYB5R3 protein binds to NAD [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine |
CTD |
PMID:16469290 PMID:25170804 |
|
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
|
|
G |
Dcxr |
dicarbonyl and L-xylulose reductase |
multiple interactions |
ISO |
1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin] |
CTD |
PMID:28595002 |
|
NCBI chr10:106,006,404...106,008,293
|
|
G |
Dek |
DEK proto-oncogene |
increases oxidation |
ISO |
DEK protein results in increased oxidation of NAD |
CTD |
PMID:28558019 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Dhrs9 |
dehydrogenase/reductase 9 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of DHRS9 protein |
CTD |
PMID:25526675 |
|
NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
|
|
G |
Enox2 |
ecto-NOX disulfide-thiol exchanger 2 |
multiple interactions |
ISO |
[epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD |
CTD |
PMID:20518072 |
|
NCBI chr X:128,270,941...128,593,074
Ensembl chr X:128,271,074...128,593,039
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
multiple interactions decreases abundance increases ADP-ribosylation increases metabolic processing |
ISO |
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein] nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] NAD results in increased ADP-ribosylation of ERCC6 protein ERCC6 gene mutant form results in increased metabolism of NAD |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Gale |
UDP-galactose-4-epimerase |
multiple interactions |
ISO |
NAD binds to and results in increased activity of GALE protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Galnt1 |
polypeptide N-acetylgalactosaminyltransferase 1 |
increases expression |
ISO |
NAD results in increased expression of GALNT1 mRNA |
CTD |
PMID:29935245 |
|
NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO EXP |
[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
EXP |
NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] |
CTD |
PMID:22561310 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases abundance multiple interactions |
ISO |
GSK3B protein mutant form results in increased abundance of NAD metabolite 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:25246272 PMID:25536389 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
NAD inhibits the reaction [Doxorubicin results in decreased activity of GSR protein] |
CTD |
PMID:24491677 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
increases metabolic processing |
ISO |
HADH protein results in increased metabolism of NAD |
CTD |
PMID:10600649 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
multiple interactions |
ISO |
[Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein |
CTD |
PMID:25526675 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hpse |
heparanase |
increases expression |
EXP |
NAD results in increased expression of HPSE mRNA; NAD results in increased expression of HPSE protein |
CTD |
PMID:19429930 |
|
NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene] |
CTD |
PMID:10334203 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
multiple interactions |
ISO |
[Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein |
CTD |
PMID:25526675 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
increases reduction multiple interactions |
EXP ISO |
HSD11B2 protein results in increased reduction of NAD Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD] |
CTD |
PMID:26859423 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsd17b10 |
hydroxysteroid (17-beta) dehydrogenase 10 |
multiple interactions |
ISO |
[20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein |
CTD |
PMID:25526675 |
|
NCBI chr X:21,089,142...21,091,603
Ensembl chr X:21,089,122...21,109,488
|
|
G |
Hsd17b11 |
hydroxysteroid (17-beta) dehydrogenase 11 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B11 protein |
CTD |
PMID:25526675 |
|
NCBI chr14:5,693,304...5,743,157
Ensembl chr14:5,711,964...5,743,161
|
|
G |
Hsd17b13 |
hydroxysteroid (17-beta) dehydrogenase 13 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B13 protein |
CTD |
PMID:25526675 |
|
NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166
|
|
G |
Hsd17b14 |
hydroxysteroid (17-beta) dehydrogenase 14 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B14 protein |
CTD |
PMID:25526675 |
|
NCBI chr 1:96,029,224...96,039,577
Ensembl chr 1:96,029,284...96,039,883
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B2 protein |
CTD |
PMID:25526675 |
|
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B4 protein |
CTD |
PMID:25526675 |
|
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Hsd17b6 |
hydroxysteroid (17-beta) dehydrogenase 6 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD17B6 protein |
CTD |
PMID:25526675 |
|
NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425
|
|
G |
Hsd17b8 |
hydroxysteroid (17-beta) dehydrogenase 8 |
multiple interactions |
ISO |
[Gossypol co-treated with NAD] binds to HSD17B8 protein |
CTD |
PMID:25526675 |
|
NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD3B1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD3B2 protein |
CTD |
PMID:25526675 |
|
NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Hsd3b7 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of HSD3B7 protein |
CTD |
PMID:25526675 |
|
NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions increases expression |
ISO |
NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] NAD results in increased expression of IGFBP1 mRNA |
CTD |
PMID:32781018 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein] |
CTD |
PMID:25536389 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Ldha |
lactate dehydrogenase A |
increases oxidation |
EXP |
LDHA protein results in increased oxidation of NAD |
CTD |
PMID:8632003 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Mir34a |
microRNA 34a |
multiple interactions decreases abundance |
ISO |
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD] |
CTD |
PMID:23834033 |
|
NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Mtarc1 |
mitochondrial amidoxime reducing component 1 |
multiple interactions |
ISO |
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine] |
CTD |
PMID:25170804 PMID:29856598 |
|
NCBI chr13:96,324,377...96,362,677
Ensembl chr13:96,339,757...96,397,796
|
|
G |
Mtarc2 |
mitochondrial amidoxime reducing component 2 |
multiple interactions |
ISO |
[MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine |
CTD |
PMID:25170804 |
|
NCBI chr13:96,362,810...96,397,284
|
|
G |
Muc2 |
mucin 2, oligomeric mucus/gel-forming |
increases expression |
ISO |
NAD results in increased expression of MUC2 mRNA |
CTD |
PMID:29935245 |
|
NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756
|
|
G |
Nadk |
NAD kinase |
increases phosphorylation |
ISO |
NADK protein results in increased phosphorylation of NAD |
CTD |
PMID:22954684 |
|
NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322
|
|
G |
Nadsyn1 |
NAD synthetase 1 |
multiple interactions |
ISO |
[NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD |
CTD |
PMID:12547821 |
|
NCBI chr 1:198,981,559...199,009,853
Ensembl chr 1:198,981,604...199,009,869
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
increases chemical synthesis multiple interactions |
ISO |
NAMPT protein results in increased chemical synthesis of NAD [[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]] |
CTD |
PMID:23834033 PMID:25505128 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Ndufs4 |
NADH:ubiquinone oxidoreductase subunit S4 |
affects abundance |
ISO |
NDUFS4 protein affects the abundance of NAD |
CTD |
PMID:21383081 |
|
NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases oxidation multiple interactions |
EXP |
NQO1 protein results in increased oxidation of NAD NAD promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3] |
CTD |
PMID:27558805 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein |
CTD |
PMID:27026705 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
P2ry1 |
purinergic receptor P2Y1 |
multiple interactions |
ISO |
P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 2:145,241,975...145,248,186
Ensembl chr 2:145,241,849...145,248,457
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases abundance affects abundance |
ISO EXP |
[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD] PARP1 protein results in decreased abundance of NAD 5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD] PARP1 protein mutant form affects the abundance of NAD [2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]] PARP1 protein affects the abundance of NAD |
CTD |
PMID:11593040 PMID:15075382 PMID:15147502 PMID:17669606 PMID:19433264 PMID:25440059 PMID:25536389 PMID:27026705 PMID:27694308 PMID:35778544 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parp10 |
poly (ADP-ribose) polymerase family, member 10 |
decreases abundance |
ISO |
PARP10 protein results in decreased abundance of NAD |
CTD |
PMID:33051211 |
|
NCBI chr 7:107,949,031...107,958,377
Ensembl chr 7:107,949,043...107,958,304
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
multiple interactions |
ISO |
PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases activity multiple interactions |
EXP |
NAD results in decreased activity of PPARG protein 3-aminobenzamide inhibits the reaction [NAD results in decreased activity of PPARG protein] |
CTD |
PMID:18815186 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppt1 |
palmitoyl-protein thioesterase 1 |
affects abundance |
ISO |
PPT1 gene mutant form affects the abundance of NAD |
CTD |
PMID:21224254 |
|
NCBI chr 5:135,121,164...135,142,048
Ensembl chr 5:135,121,163...135,142,048
|
|
G |
Rdh10 |
retinol dehydrogenase 10 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of RDH10 protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:3,186,671...3,215,572
Ensembl chr 5:3,188,445...3,215,572
|
|
G |
Rdh16 |
retinol dehydrogenase 16 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of RDH16 protein |
CTD |
PMID:25526675 |
|
NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124
|
|
G |
Rdh5 |
retinol dehydrogenase 5 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of RDH5 protein |
CTD |
PMID:25526675 |
|
NCBI chr 7:1,341,172...1,346,863
Ensembl chr 7:1,340,934...1,351,558
|
|
G |
Sdr16c5 |
short chain dehydrogenase/reductase family 16C, member 5 |
affects activity multiple interactions |
ISO |
NAD affects the activity of SDR16C5 protein NAD binds to and results in increased activity of SDR16C5 protein |
CTD |
PMID:18926804 PMID:25526675 |
|
NCBI chr 5:17,018,813...17,043,974
Ensembl chr 5:17,018,813...17,040,970
|
|
G |
Sdr9c7 |
short chain dehydrogenase/reductase family 9C, member 7 |
multiple interactions |
ISO |
NAD binds to and results in increased activity of SDR9C7 protein |
CTD |
PMID:25526675 |
|
NCBI chr 7:63,703,788...63,720,325
Ensembl chr 7:63,707,071...63,721,480
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases response to substance increases activity decreases abundance |
ISO EXP |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein] SIRT1 protein results in increased susceptibility to NAD NAD results in increased activity of SIRT1 protein [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]] |
CTD |
PMID:19288225 PMID:19928762 PMID:22561310 PMID:23834033 PMID:25536389 PMID:34216621 More...
|
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Smpd2 |
sphingomyelin phosphodiesterase 2 |
affects activity |
ISO |
NAD affects the activity of SMPD2 protein |
CTD |
PMID:20518072 |
|
NCBI chr20:44,986,229...44,989,343
Ensembl chr20:44,986,231...44,989,441
|
|
G |
Sphk1 |
sphingosine kinase 1 |
decreases activity |
ISO |
NAD results in decreased activity of SPHK1 protein |
CTD |
PMID:20518072 |
|
NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240
|
|
G |
Taldo1 |
transaldolase 1 |
decreases abundance |
ISO |
TALDO1 gene mutant form results in decreased abundance of NAD |
CTD |
PMID:19436114 |
|
NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974
|
|
G |
Tgds |
TDP-glucose 4,6-dehydratase |
multiple interactions |
ISO |
NAD binds to and results in increased activity of TGDS protein |
CTD |
PMID:25526675 |
|
NCBI chr15:95,175,064...95,195,555
Ensembl chr15:95,174,608...95,195,554
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions decreases expression |
ISO |
[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein] NAD results in decreased expression of TP53 protein |
CTD |
PMID:10334203 PMID:11461765 PMID:12390773 PMID:34216621 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tyr |
tyrosinase |
multiple interactions increases oxidation |
ISO |
ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD] |
CTD |
PMID:20685355 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Uxs1 |
UDP-glucuronate decarboxylase 1 |
multiple interactions |
ISO |
[thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:653,740...731,121
Ensembl chr 9:653,659...756,334
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
decreases reduction multiple interactions |
ISO |
XRCC1 gene mutant form results in decreased reduction of NAD [XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]] |
CTD |
PMID:30998386 PMID:35778544 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|